CARL WEISSMAN

Profile

First Name

: CARL

Middle Name

:

Last Name

: WEISSMAN

Related Companies
Titles
Company Name
Related People
DIRECTOR
XORI CORP
FRED ESHELMAN, STEVE GILLIS, THONG LE, STUART J. MACKEY, NANCY MAIZELS, LINDSAY RAYLE, DAVID SCHUBERT, CHAD WAITE
DIRECTOR
NOVOMER INC
SCOTT D. ALLEN, GEOFFREY COATES, PH.D., TONY EISENHUT, JAMES MAHONEY, JAMES MATHESON, ROBERT PANGBORN, PETER SHEPARD, CORY D. STEFFEK, RON VALENTE, ANDREW WILLIAMSON
DIRECTOR
FATE THERAPEUTICS INC
STEWART ABBOT, SHEFALI AGARWAL, TIMOTHY COUGHLIN, TIMOTHY P. COUGHLIN, MARK ENYEDY, MARK J. ENYEDY, ROBERT EPSTEIN, ROBERT S. EPSTEIN, PAUL GRAYSON, ROBERT HERSHBERG, KARIN JOOSS, MICHAEL LEE, JOHN MENDLEIN, AMIR NASHAT, ROBERT NELSEN, ROBERT T. NELSEN, WILLIAM RASTETTER, BRYAN ROBERTS, BRYAN E. ROBERTS, DANIEL SHOEMAKER, DANIEL D. SHOEMAKER, CHRIS STORGARD, CINDY TAHL, CHRISTIAN WEYER, J. SCOTT WOLCHKO, SCOTT WOLCHKO
EXECUTIVE OFFICER, DIRECTOR
MIRINA CORP
BRIAN ATWOOD, STEVEN GILLIS, MERL F. HOEKSTRA, THONG LE, LINDSAY RAYLE, DAVID SCHUBERT, CHAD WAITE
DIRECTOR, EXECUTIVE OFFICER
ACYLIN THERAPEUTICS, INC.
LEE BABISS, PETER DISTEFANO, STEVEN GILLIS, STEVEN GILLS, THONG LE, JANIS NAEVE, LINDSAY RAYLE, CHAD WAITE
EXECUTIVE OFFICER, DIRECTOR
ONCOFACTOR CORP
LEE BABISS, STEVE GILLIS, THONG LE, DAVID MCELLIGOTT, JANIS NAEVE, LINDSAY RAYLE, DAVID SCHUBERT, CHAD WAITE
EXECUTIVE OFFICER, DIRECTOR
GROOVE BIOPHARMA CORP
BRIAN ATWOOD, STEVEN GILLIS, MERL F. HOEKSTRA, THONG LE, LINDSAY RAYLE, DAVID SCHUBERT, CHAD WAITE
DIRECTOR
ALLOZYNE INC
JOHN BENCICH, MEENU CHHABRA, STEVEN GILLIS, KENNETH GRABSTEIN, MICHAEL STEINMETZ, DAVID TIRRELL
DIRECTOR
VIRAL LOGIC SYSTEMS TECHNOLOGY CORP
BRIAN BLACKMAN, TERESA FOY, STEVEN GILLIS, RON M. MYERS, GREGORY SESSLER, MARTIN A. SIMONETTI, DAVID URDAL
DIRECTOR
MATRIX GENETICS, LLC
SIMON BEST, J. KUMAR, MARGARET MCCORMICK, JAMES ROBERTS
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2015-12-16
D
Link
OTHER 
 
DECLINE TO DISCLOSE 
Debt 
2015-12-01 
2013-12-10
D
Link
OTHER TECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2013-11-25 
2013-09-03
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2013-08-22 
2013-08-16
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2013-03-22 
2013-08-13
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Debt 
2013-08-08 
2013-04-05
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2013-03-22 
2012-08-31
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-08-17 
2012-08-21
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-05-04 
2012-06-14
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-06-11 
2012-06-04
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-05-23 
2012-06-01
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2012-05-25 
2012-05-18
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
 
2012-05-10 
2012-02-03
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2012-01-25 
2011-12-20
D
Link
OTHER HEALTH CARE 
 
DECLINE TO DISCLOSE 
Equity 
2011-12-07 
2011-10-28
D
Link
OTHER TECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2011-10-14 
2011-05-19
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2011-05-05 
2011-04-20
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2009-11-10 
2011-04-20
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2011-03-30 
2010-12-01
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2010-11-18 
2010-12-01
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2010-11-17 
2010-04-28
D
Link
OTHER HEALTH CARE 
 
DECLINE TO DISCLOSE 
Equity 
2010-04-16 
2009-12-24
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2009-11-10 
2009-11-23
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2009-11-10 
2009-08-24
D
Link
OTHER TECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2009-08-12 
2009-05-15
D/A
Link
BIOTECHNOLOGY 
 
NO REVENUES 
Equity 
2009-05-01 
2009-05-15
D
Link
BIOTECHNOLOGY 
 
NO REVENUES 
Equity 
2009-05-01